21st Austria weekly - Marinomed Vienna Insurance Group 21/11/2023 [pic1]Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters 2023 Q1-Q3 2022: 7.1 million due to continued demand for Carragelose virus blockers. The increase personnel costs higher R&D expenses and lower research subsidies were reflected operating result -4.4 -3.8 million. period amounted -5.6 million compared -5.8 prior-year period. For platform took necessary steps create an all-year product portfolio a expansion therapeutic area immunology with allergy blocker eye drops. market launches are already preparation 2024. Procter & Gamble also secured rights Carragelose-based spray USA. has paved way further important partnerships candidates Budesolv Tacrosolv which based on Marinosolv
The Hague, February 16, 2022 - Aegon has taken note of the announcement issued today by Vienna Insurance Group AG Wiener Versicherung Gruppe (VIG) about.
The Hague, February 16, 2022- Aegon has taken note of the announcement issued today by Vienna Insurance Group AG Wiener Versicherung Gruppe about the agreement reached between VIG and the Hungarian state holding Corvinus Nemzetközi Befektetési Zrt. on the details of their cooperation which had been broadly defined in the Memorandum of Understanding.
The Hague, February 16, 2022 - Aegon has taken note of the announcement issued today by Vienna Insurance Group AG Wiener Versicherung Gruppe (VIG) about the agreement reached between VIG and the Hungarian